NED Medical
Norwell, US · Founded 2022 · Delaware corporation
NED Medical develops CombiSphere, a Y90 radioembolization therapy made with proprietary materials offering optimized particle size, density, radiopacity, and dosimetry to treat liver cancer. The product is aimed at clinicians treating oncology patients through embolization therapy.
Founders & leadership
RY

Richard YazbeckinExecutive
AT

Andrew ThoresonNamed on SEC filing
Board
RM
Robert Matthew NiblackBoard director
DU

David UfferBoard director
JM
James MitchellBoard director
GJ
Gregory J KapustBoard director
Reported raises · per SEC filings
Form D private placements$8.5M disclosed across 2 rounds · 2023–2026
▶$8MraisedFeb 2026 · 3 investors · Other Health CareRule 506(b)
▶$8MraisedFeb 2026 · 3 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Robert Matthew NiblackDirector
- David UfferDirector
- James MitchellDirector
- Richard YazbeckExecutive Officer, Director
- Gregory J KapustDirector
- Offering amount
- $11M
- Amount sold
- $8M
- First sale
- Jan 2026
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
▶$500KraisedAug 2023 · 2 investors · Other Health CareRule 506(b)
▶$500KraisedAug 2023 · 2 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Richard YazbeckDirector
- Robert Matthew NiblackDirector
- David UfferDirector
- Andrew ThoresonDirector
- Offering amount
- $1.8M
- Amount sold
- $500K
- First sale
- Aug 2023
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlapCompanies competing with NED Medical for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does NED Medical do?
- NED Medical develops CombiSphere, a Y90 radioembolization therapy made with proprietary materials offering optimized particle size, density, radiopacity, and dosimetry to treat liver cancer. The product is aimed at clinicians treating oncology patients through embolization therapy.
- How much funding has NED Medical raised?
- NED Medical has disclosed $8.5M raised across 2 rounds.
- Where is NED Medical headquartered?
- NED Medical is headquartered in Norwell, US.
